Regulatory T cells (Tregs) are T cells that function to regulate other cells in the immune system through various contact-dependent and independent mechanisms. They are vital in preventing and controlling excessive immune responses and autoimmunity. As of now, there is no approved marketed product available in the global market for Regulatory T-Cell Therapies. Based on our estimates, Regulatory T-Cell (Tregs) Therapies Market is estimated to grow at a 40.0% CAGR during the forecast period for 2026-2035.
The multiple factors driving the growth of the Regulatory T-Cell Therapies (Tregs) Market include the rising chronic conditions such as autoimmune diseases, allergies, & organ transplantation, increasing technological advances in therapy techniques, surging demand for cost-efficient immunotherapies, growing awareness among people regarding the advantages of T-cell therapeutics, and increasing government support for the R&D of innovative regulatory T-cell therapies. The companies operating in this market are collaborating with technologies companies to develop & commercialize Treg therapies. For instance, in June 9, 2023 AstraZeneca collaborated with Quell to develop regulatory T cell therapies for Type 1 diabetes and inflammatory bowel disease. Similarly, in September 2021, Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, collaborated with Genentech to develop and commercialize allogeneic T cell therapies and to treat multiple oncology indications. Therefore, increasing collaborations are projected to accelerate market expansion in the future. However, the cost of regulatory T-cell therapies, poor reimbursement policies for cell therapies, side effects associated with these therapies, and the complicated production and supply chain methods may impede the market growth in the upcoming years.
Market Segmentation
The Regulatory T-Cell Therapies (Tregs) Market is classified based on therapeutic area, products, source of T-cells and region. Based on therapeutic area the market is segmented into autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders, dermatological disorders. By-products, the market is segmented into Tregs, interleukin 2, monoclonal antibodies, small molecules, CAR-Treg and other products. The Tregs segment is expected to dominate this market during the forecast years due to its increasing therapeutic applications. The Source of T-Cells segment comprises autologous and allogeneic. Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. The North America regional segment is anticipated to dominate the regulatory T-cell therapies (Tregs) Market over the forecast period (2026-2035), owing to the increasing pharmaceutical R&D expenditure and the rising number of clinical trials for T-cell therapies in this region.
Competitive Landscape
Some major key players in the Regulatory T-Cell (Tregs) Therapies Market:
- Abata Therapeutics (US),
- Cellenkos Inc (US),
- Coya Therapeutics (US),
- Roche (Switzerland),
- Lisata Therapeutics
- Sonoma Biotherapeutics (US),
- Nektar Therapeutics (US),
- Eli Lilly and Company (US),
- Baudax Bio
- TRACT Therapeutics (US),
- VT Bio (South Korea),
- Sangamo Therapeutics (TxCell) (US),
- TRexBio
- Mozart Therapeutics
- Pfizer Inc. (US), PolTREG S.A.. (Poland),
- Parvus Therapeutics (Canada)
- ILTOO Pharma (France),
- GentiBio
- Tr1X
- Quell Therapeutics
- AstraZeneca
- Kyverna Therapeutics, Inc.
- Others
The Regulatory T-Cell (Tregs) Therapies Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 40.0% from 2026 to 2035 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2026 to 2030 |
|
Historic Year |
2025-2035 |
|
Forecast Year |
2026-2035 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Therapeutic Area, Product, Source of T-Cells |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Abata Therapeutics (US), Cellenkos Inc (US), Coya Therapeutics (US), Roche (Switzerland), Lisata Therapeutics, Sonoma Biotherapeutics (US), Nektar Therapeutics (US), Eli Lilly and Company (US), Baudax Bio, TRACT Therapeutics (US), VT Bio (South Korea), Sangamo Therapeutics (TxCell) (US), TRexBio, Mozart Therapeutics, Pfizer Inc. (US), PolTREG S.A. (Poland), Parvus Therapeutics (Canada), ILTOO Pharma (France), GentiBio, Tr1X, Quell Therapeutics, AstraZeneca, Kyverna Therapeutics, Inc., Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Global Regulatory T-Cell Therapies (Tregs) Market, by Products, 
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
